Sanofi says lunsekimig hit Phase 2 endpoints in asthma and CRSwNP, showing dual TSLP/IL-13 blockade and solid safety—read ...

AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session Across the COAST 1, COAST 2, and SHORE phase 3 studies, amlitelimab, dosed ...

Tuesday, French drugmaker Sanofi SA (NASDAQ:SNY) announced its collaboration with OpenAI and Formation Bio to accelerate drug development projects. Also Read: Drugmaker Sanofi’s Strong Dupixent And ...

Sanofi (NASDAQ:SNY) is preparing to release its quarterly earnings on Thursday, 2026-01-29. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect ...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Sanofi (NASDAQ:SNY) is one of the best 52-week low blue-chip stocks to buy right now. On January 29, Sanofi SA (NASDAQ:SNY) reiterated plans to conduct a €1 billion share buyback in 2026. The buyback ...

Sanofi SA (NASDAQ:SNY) is one of the best cheap stocks to buy for 2026. On January 27, Citi Research initiated coverage of six large European pharmaceutical stocks, including Sanofi SA (NASDAQ:SNY), ...

Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in moderate ...